Page 343 - Glucose Monitoring Devices

350 CHAPTER 16 The dawn of automated insulin delivery

[33] Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, et al. Predictive
low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with
type 1 diabetes in an at-home randomized crossover study: results of the PROLOG
trial. Diabetes Care 2018;41(10):2155e61.
[34] Pinsker JELZ, Buckingham BA, Forlenza GP, Cengiz E, Church MM, et al. Excep-
tional usability of Tandem t:slim X2 with Basal-IQ predictive low-glucose suspend
(PLGS)dthe PROLOG study. Orlando, Florida: American Diabetes Association
Scientific Session; 2018.
[35] Beck RW, Raghinaru D, Wadwa RP, Chase HP, Maahs DM, Buckingham BA, et al.
Frequency of morning ketosis after overnight insulin suspension using an automated
nocturnal predictive low glucose suspend system. Diabetes Care 2014;37(5):1224e9.
[36] Doyle 3rd FJ, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed-loop artificial
pancreas systems: engineering the algorithms. Diabetes Care 2014;37(5):1191e7.
[37] Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of
concept in closed-loop control of type 1 diabetes. Journal of Diabetes Science and
Technology 2009;3(1):44e55.
[38] Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, et al. Multinational
study of subcutaneous model-predictive closed-loop control in type 1 diabetes melli-
tus: summary of the results. Journal of Diabetes Science and Technology 2010;4(6):
1374e81.
[39] Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin
delivery for the treatment of type 1 diabetes. Diabetes 2006;55(12):3344e50.
[40] Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully
automated closed-loop insulin delivery versus semiautomated hybrid control in pedi-
atric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;
31(5):934e9.
[41] Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, et al. The “Glucosit-
ter” overnight automated closed loop system for type 1 diabetes: a randomized cross-
over trial. Pediatric Diabetes 2013;14(3):159e67.
[42] El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal
closed-loop artificial pancreas for type 1 diabetes. Science Translational Medicine
2010;2(27):27ra.
[43] Nimri R, Atlas E, Ajzensztejn M, Miller S, Oron T, Phillip M. Feasibility study of auto-
mated overnight closed-loop glucose control under MD-logic artificial pancreas in pa-
tients with type 1 diabetes: the DREAM Project. Diabetes Technology and
Therapeutics 2012;14(8):728e35.
[44] Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV,
et al. Mitigating meal-related glycemic excursions in an insulin-sparing manner during
closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and
liraglutide. Diabetes Care 2016;39(7):1127e34.
[45] Weinzimer SA, Sherr JL, Cengiz E, Kim G, Ruiz JL, Carria L, et al. Effect of pramlin-
tide on prandial glycemic excursions during closed-loop control in adolescents and
young adults with type 1 diabetes. Diabetes Care 2012;35(10):1994e9.
[46] Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, et al. Glucose-
responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults
with type 1 diabetes: a randomized crossover controlled trial. Canadian Medical Asso-
ciation Journal 2013;185(4):297e305.